The study by Abrahami et al. also suggested an increased risk of cholangiocarcinoma associated with the use of DPP-4 inhibitors and GLP-1 RAs, but the study involving GLP-1 RAs had a wide confidence interval, leading to some uncertainty in the conclusion (Abrahami et al., 2018). This evidence concerns the gene DPP4 and cholangiocarcinoma.